167 related articles for article (PubMed ID: 37564940)
1. A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer.
Liu H; Luo M; Peng C; Huang J; Wang D; Huang J; Zhang G
Front Oncol; 2023; 13():1103357. PubMed ID: 37564940
[TBL] [Abstract][Full Text] [Related]
2. Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer.
Sørensen SM; Høgdall C; Mosgaard BJ; Dalgaard MIR; Jensen MP; Fuglsang K; Schnack TH
Acta Obstet Gynecol Scand; 2022 Mar; 101(3):334-343. PubMed ID: 35187660
[TBL] [Abstract][Full Text] [Related]
3. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
[TBL] [Abstract][Full Text] [Related]
4. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer.
Métairie M; Benoit L; Koual M; Bentivegna E; Wohrer H; Bolze PA; Kerbage Y; Raimond E; Akladios C; Carcopino X; Canlorbe G; Uzan J; Lavoué V; Mimoun C; Huchon C; Koskas M; Costaz H; Margueritte F; Dabi Y; Touboul C; Bendifallah S; Ouldamer L; Delanoy N; Nguyen-Xuan HT; Bats AS; Azaïs H
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765667
[TBL] [Abstract][Full Text] [Related]
5. Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer.
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Surg Oncol; 2020 Aug; 122(2):315-319. PubMed ID: 32500598
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
7. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases.
Yasunaga M; Yahata H; Okugawa K; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Int J Clin Oncol; 2021 Jul; 26(7):1330-1335. PubMed ID: 33786711
[TBL] [Abstract][Full Text] [Related]
10. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
Wang D; Zhang G; Peng C; Shi Y; Shi X
J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
[TBL] [Abstract][Full Text] [Related]
11. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
12. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
[TBL] [Abstract][Full Text] [Related]
13. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
14. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Haldar K; Kehoe S; Lawrie TA
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
[TBL] [Abstract][Full Text] [Related]
16. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
18. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
20. Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer.
Timmermans M; Sonke GS; Van de Vijver KK; Ottevanger PB; Nijman HW; van der Aa MA; Kruitwagen RFPM
Int J Gynecol Cancer; 2019 Feb; 29(2):392-397. PubMed ID: 30665898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]